What type of drug is Zilucoplan?

Zilucoplan is a synthetic peptide drug that targets the complement system. Its pharmacological classification is "C5 complement protein inhibitor" and is specially designed for patients with myasthenia gravis (gMG; rare disease) who are positive for acetylcholine receptor antibodies (AChR-Ab+). Its mechanism of action is to selectively block the key C5 protein in the complement cascade, thereby preventing the formation of the membrane attack complex (MAC) at the neuromuscular junction, reducing the immune system's attack on nerve endings, and ultimately improving myasthenia symptoms.

Myasthenia gravis is a typical autoimmune disease, and its pathogenesis is mainly related to the destruction of neuromuscular connections mediated by anti-AChR antibodies. When antibodies continue to attack acetylcholine receptors at nerve terminals, the complement system will be activated, triggering local inflammation and the generation of terminal attack complexes, resulting in impaired nerve impulse transmission, resulting in symptoms such as muscle weakness, dysphagia, diplopia, and upper and lower limb weakness. By blocking this core mechanism, Zilucoplan effectively interrupts the complement destruction pathway and is currently one of the cutting-edge methods for treating the cause of gMG.

The biggest advantage of zeleptide is that it has precise targets and acts on specific links of the immune system. Compared with traditional immunosuppressants such as glucocorticoids, immunoglobulins or immunomodulatory drugs, it has fewer immune side effects and better overall patient tolerance. At the same time, the drug is a daily subcutaneous injection, which has a rapid onset of action and allows patients to self-inject at home, improving compliance and treatment continuity. It is extremely convenient for long-term management of myasthenia gravis.

It is worth noting that the clinical applicable population of zeleptide is mainly gMG patients who are AChR-Ab positive and is not suitable for MuSK antibody-positive or dual-antibody-negative patients. This also reflects the highly individualized tendency of modern precision medicine in drug selection. As one of the only complement-targeted treatments currently available, the launch of zeleptide brings new hope to many patients who have poor response to traditional treatments or intolerable side effects.

Reference materials:https://www.drugs.com/zilucoplan.html